BioVentrix Expands Life-Extending Transcatheter Heart Failure Treatment To Second European Clinical Site

SAN RAMON, Calif. & PRAGUE--(BUSINESS WIRE)--BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced that placement of its Revivent-TC™ Ventricular Enhancement System, via Less Invasive Ventricular Enhancement™ or the LIVE™ procedure, has been successfully expanded to a second European clinical site. The procedure, which is used to reshape and reduce the left ventricle (LV), was performed on a 64-year-old man suffering from ischemic heart failure. Performed by Prof. Petr Neuzil and Dr. Ivo Skalsky at Na Holmoce Hospital in Prague, Czech Republic, the transcatheter procedure was performed without opening the patient’s chest and without the use of a heart-lung bypass machine.